middl
east
respiratori
syndrom
mer
newli
emerg
infecti
diseas
caus
novel
coronaviru
merscoronaviru
merscov
new
member
lineag
c
increas
human
case
high
mortal
rate
merscov
infect
make
essenti
develop
safe
effect
vaccin
review
current
advanc
potenti
strategi
develop
mer
vaccin
particularli
subunit
vaccin
base
merscov
spike
protein
receptorbind
domain
rbd
discuss
improv
efficaci
subunit
vaccin
novel
adjuv
formul
rout
administr
well
current
avail
anim
model
evalu
vivo
efficaci
merscov
vaccin
also
address
overal
strategi
may
import
implic
develop
effect
safe
vaccin
merscov
futur
novel
name
middl
east
respiratori
syndrom
mer
coronaviru
merscov
first
identifi
human
middl
east
june
viru
isol
saudi
man
diagnos
progress
communityacquir
pneumonia
subsequ
acut
renal
failur
fatal
outcom
increas
number
case
result
merscov
infect
shown
figur
march
total
human
merscov
infect
death
report
middl
east
north
africa
sever
european
countri
mani
anim
consid
reservoir
cov
origin
merscov
mode
diseas
transmiss
still
remain
unknown
base
sequenc
fragment
ident
merscov
found
taphoz
perfor
bat
captur
saudi
arabia
infer
bat
like
reservoir
merscov
identif
merscov
dromedari
camel
detect
neutral
antibodi
sera
anim
suggest
camel
could
intermedi
host
merscov
thu
suspect
merscov
emerg
interspeci
transmiss
bat
anim
camel
human
sever
famili
cluster
merscov
infect
report
suggest
humantohuman
transmiss
diseas
peopl
infect
merscov
develop
sever
acut
respiratori
ill
symptom
like
fever
cough
short
breath
viru
estim
incub
period
day
transmiss
merscov
human
current
less
effici
sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
guangdong
provinc
china
reemerg
case
death
countri
throughout
world
nonetheless
mortal
rate
mer
much
higher
sar
report
merscov
sarscov
could
replic
cell
line
four
major
chiropteran
famili
impli
abil
merscov
cross
speci
barrier
human
bat
increas
human
case
high
mortal
rate
merscov
infect
rais
seriou
global
concern
although
still
earli
implic
impend
pandem
vaccin
consid
one
effect
strategi
prevent
viru
infect
thu
develop
effect
vaccin
essenti
fight
infecti
diseas
propos
coronaviru
studi
group
intern
committe
taxonomi
virus
ictv
three
group
coronavirida
famili
commonli
accept
respect
genu
consist
four
lineag
name
b
c
novel
genu
includ
identifi
bird
ad
cov
genera
unlik
previous
identifi
cov
alphacov
first
report
well
first
discov
hong
kong
sarscov
caus
worldwid
outbreak
merscov
belong
lineag
c
first
known
lineag
c
associ
human
infect
phylogenet
merscov
close
relat
bat
cov
merscov
positivesens
singlestrand
rna
viru
genom
kilobas
pair
kb
length
consist
function
open
read
frame
orf
figur
tabl
viral
genom
encod
five
uniqu
protein
known
accessori
protein
serv
differ
function
known
homologu
cov
protein
accessori
protein
exampl
recent
proven
block
product
host
interferon
ifn
although
accessori
protein
essenti
viru
replic
recent
studi
revers
genet
demonstr
absenc
gene
encod
protein
group
may
attenu
viral
titer
addit
genom
merscov
encod
six
protein
homolog
known
cov
includ
two
replicas
protein
orf
four
major
structur
protein
spike
envelop
e
membran
nucleocapsid
n
protein
figur
e
protein
transmembran
protein
form
ion
channel
viral
surfac
cov
n
protein
play
import
role
encapsid
genom
rna
interact
protein
n
molecul
protein
cov
type
transmembran
glycoprotein
display
oligom
surfac
viral
membran
precursor
protein
contain
cleavag
site
protein
could
cleav
two
noncoval
associ
subunit
distal
subunit
membraneanchor
subunit
subunit
contain
cellular
receptorbind
domain
rbd
subunit
contain
put
fusion
peptid
transmembran
domain
two
heptad
repeat
region
heptad
repeat
figur
figur
list
repres
structur
protein
mous
hepat
cov
mhvcov
sarscov
rbd
cov
protein
consist
respect
core
receptorbind
subdomain
exampl
receptorbind
motif
sarscov
contain
residu
form
long
extend
loop
two
short
antiparallel
one
disulfid
bond
similar
protein
cov
protein
merscov
also
contain
subunit
respons
receptor
bind
membran
fusion
unlik
cov
sarscov
use
human
angiotensinconvert
enzym
receptor
merscov
util
human
dipeptidyl
peptidas
also
known
cellular
receptor
express
primari
bronchiolar
epitheli
cell
regul
activ
hormon
chemokin
proteolyt
cleavag
recent
studi
solv
crystal
structur
merscov
protein
alon
complex
receptor
map
rbd
merscov
residu
cover
respect
accord
crystal
structur
rbd
merscov
also
contain
core
receptorbind
subdomain
receptorbind
motif
consist
amino
acid
form
fourstrand
antiparallel
figur
similar
cov
merscov
form
bundl
believ
drive
virioncel
membran
fusion
three
helic
form
central
coiledcoil
core
three
chain
surround
core
side
groov
figur
describ
crystal
structur
sarscov
merscov
rbd
complex
respect
receptor
major
neutral
epitop
sarscov
rbd
neutral
monoclon
antibodi
sarscov
understand
neutral
epitop
rbd
sarscov
provid
use
guidanc
identif
neutral
epitop
merscov
rbd
henc
design
rbdbase
neutral
epitopedepend
vaccin
merscov
previou
review
sar
summar
approach
develop
effect
cov
vaccin
point
import
sarscov
protein
target
vaccin
therapeut
develop
outlin
roadmap
product
develop
sarscov
rbd
proteinbas
subunit
vaccin
manufactur
futur
clinic
test
review
briefli
discuss
current
stage
mer
vaccin
develop
provid
potenti
strategi
develop
mer
vaccin
base
experi
develop
sar
vaccin
focu
subunit
vaccin
improv
efficaci
mer
subunit
vaccin
addit
also
summar
current
anim
model
merscov
emphas
import
evalu
efficaci
mer
vaccin
candid
effect
anim
model
current
licens
mer
vaccin
avail
use
howev
research
work
develop
potenti
vaccin
recent
success
engin
replicationcompet
propagationdefect
merscov
use
revers
genet
provid
possibl
develop
attenu
virus
mer
vaccin
candid
sar
studi
demonstr
vaccin
induc
strong
neutral
antibodi
complet
protect
immun
subject
sarscov
infect
moreov
recov
patient
infect
sarscov
could
maintain
potent
persist
rbdspecif
antibodi
respons
neutral
activ
reveal
signific
neutral
antibodi
prevent
sar
like
case
sarscov
vaccin
although
vaccin
elicit
favor
cellular
immun
respons
may
play
role
clearanc
viru
infect
vaccin
induc
neutral
antibodi
suffici
protect
merscov
infect
thu
abil
elicit
neutral
antibodi
expect
one
import
criteria
evalu
efficaci
mer
vaccin
previou
studi
sarscov
shown
protein
particularli
rbd
may
induc
highli
potent
neutral
antibodi
protect
vaccin
anim
sarscov
challeng
thu
expect
protein
merscov
also
import
develop
vaccin
song
et
al
shown
vaccin
recombinantmodifi
vaccinia
viru
ankara
mva
express
fulllength
protein
merscov
induc
high
level
neutral
antibodi
vaccin
mice
howev
cao
colleagu
report
although
mvabas
fulllength
proteindepend
sar
vaccin
could
induc
neutral
antibodi
respons
ferret
fail
protect
vaccin
anim
sarscov
challeng
even
wors
vaccin
associ
enhanc
inflammatori
immunopatholog
effect
result
seriou
liver
damag
vaccin
ferret
viral
challeng
therefor
caution
taken
fulllength
protein
merscov
use
vaccin
antigen
sinc
nonneutr
epitop
protein
may
induc
antibodymedi
diseas
enhanc
ade
effect
elicit
protein
felin
infecti
periton
viru
fipv
also
cov
therefor
favor
develop
vaccin
base
protein
fragment
particularli
rbd
merscov
strategi
report
effect
develop
mer
vaccin
studi
shown
neutral
merscov
infect
could
elicit
vaccin
rabbit
fragment
contain
residu
merscov
protein
induct
neutral
activ
recombin
protein
fragment
contain
residu
merscov
rbd
also
demonstr
particularli
truncat
acid
rbd
fragment
contain
residu
insid
rbd
residu
merscov
protein
induc
strong
merscov
sspecif
antibodi
vaccin
mice
block
bind
merscov
rbd
viral
receptor
effect
neutral
merscov
infect
thu
provid
promis
develop
effect
safe
mer
vaccin
addit
protein
merscov
viral
protein
might
play
role
develop
mer
candid
vaccin
howev
studi
address
possibl
particular
mer
recent
emerg
novel
human
diseas
vaccin
develop
timeconsum
process
recent
studi
reveal
structur
accessori
protein
orf
orf
orf
merscov
may
function
potent
ifn
antagonist
orf
protein
show
greatest
potenti
counteract
antivir
effect
ifn
inhibit
ifn
product
ifnsensit
respons
element
signal
pathway
therefor
protein
may
also
serv
target
develop
mer
vaccin
tradit
inactiv
liveattenu
viru
vaccin
commonli
develop
use
vaccin
type
viral
pathogen
includ
sarscov
type
vaccin
base
dna
viral
vector
viruslik
particl
vlp
recombin
protein
also
discuss
term
potenti
applic
mer
vaccin
candid
paper
relat
merscov
vaccin
develop
publish
far
rest
review
discuss
develop
sarscov
vaccin
learn
best
strategi
develop
merscov
vaccin
move
forward
effici
main
advantag
disadvantag
differ
strategi
cov
vaccin
develop
list
tabl
sarscov
test
vaccin
candid
proven
effect
provid
protect
immun
sarscov
infect
previous
report
sarscov
vaccin
administ
subcutan
sc
mice
effect
inhibit
viru
replic
murin
respiratori
tract
adenovirusbas
n
vaccin
given
either
intranas
intramuscularli
im
addit
live
impairedfidel
sarscov
vaccin
engin
inactiv
exonucleas
activ
protect
age
immunocompromis
mice
lethal
viru
challeng
appar
local
serum
antibodi
respons
induc
inactiv
sarscovvaccin
mice
like
sarscov
might
possibl
attenu
merscov
delet
envelop
e
protein
diminish
viru
growth
tissu
cultur
abrog
virul
anim
inactiv
exonucleas
activ
spite
possibl
induc
highli
potent
immun
respons
protect
vaccin
candid
base
inactiv
liveattenu
merscov
might
potenti
recov
virul
rais
safeti
concern
vaccin
type
may
inappropri
use
highli
immunosuppress
individu
dna
vaccinesdna
vaccin
consist
plasmid
dna
genet
engin
produc
immunolog
respons
protect
organ
diseas
dna
usual
administ
two
rout
im
deliveri
bombard
skin
use
gene
gun
current
two
popular
theori
dna
uptak
use
includ
nonspecif
phagocytosi
pinocytosi
antigenspecif
receptormedi
uptak
contain
nonrepl
noninfecti
compon
encod
protein
interest
dna
vaccin
safe
use
minim
undesir
side
effect
addit
vaccin
base
dna
easi
scale
ferment
techniqu
gener
stabl
inexpens
efficaci
dnabas
vaccin
sarscov
infect
wide
review
reveal
dna
vaccin
encod
sarscov
protein
induc
neutral
antibodi
well
cell
respons
protect
vaccin
mice
sarscov
challeng
addit
igg
antibodi
cellmedi
immun
respons
induc
dna
vaccin
encod
sarscov
interestingli
express
protein
sarscov
augment
immun
respons
induc
np
protein
sarscov
dna
vaccin
nevertheless
compar
vaccin
type
inactiv
liveattenu
viru
vaccin
dnabas
vaccin
usual
lower
immunogen
indic
need
improv
immun
efficaci
although
possibl
use
similar
strategi
develop
dnabas
vaccin
merscov
infect
suitabl
measur
primingboost
strategi
combin
dna
vaccin
vaccin
type
consid
improv
immunogen
dnabas
mer
vaccin
viral
vectorbas
vaccinesvir
vector
appli
import
deliveri
vehicl
develop
candid
vaccin
sarscov
infect
current
report
viral
vector
sar
vaccin
includ
mva
vesicular
stomat
viru
rhabdoviru
adenoviru
adenoassoci
viru
attenu
parainfluenzaviru
previou
report
indic
abil
mvabas
vaccin
express
sarscov
protein
induct
neutral
antibodi
protect
vaccin
mice
sarscov
challeng
addit
combin
adenoviralbas
sar
vaccin
encod
np
protein
respect
induc
strong
neutral
antibodi
tcell
immun
respons
protect
immun
monkey
challeng
sarscov
induct
suffici
cellular
humor
immun
respons
also
demonstr
neutral
activ
adenoassoci
virusbas
vaccin
contain
rbd
sarscov
protect
sarscov
challeng
approach
develop
viral
vectorbas
sar
vaccin
adopt
develop
mer
vaccin
inde
merscov
protein
deliv
mva
vector
induc
vaccin
mice
antibodi
respons
neutral
activ
bring
hope
develop
viral
vectorbas
vaccin
prevent
merscov
infect
howev
note
viral
vectorbas
vaccin
disadvantag
exampl
vector
mva
adenoviru
preexist
immun
caus
harm
immun
respons
inflamm
thu
caution
taken
develop
mer
vaccin
use
viral
vector
vlp
vaccinesvlpbas
vaccin
develop
new
gener
noneggbas
cell
culturederiv
vaccin
candid
viru
infect
thu
gain
much
attent
potenti
promis
develop
effect
safe
vaccin
sarscov
vlp
produc
sever
express
system
mammalian
cell
eg
cho
yeast
recombin
vaccinia
viru
baculoviru
express
system
worth
note
minim
compon
essenti
vlp
format
immunogen
induc
vlp
need
consid
although
e
protein
sarscov
suffici
effici
format
vlp
immunogen
induc
vlp
without
protein
might
greatli
reduc
comparison
chimer
vlp
carri
sarscov
protein
e
n
protein
mhvcov
elicit
high
level
sarscovspecif
neutral
antibodi
protect
vaccin
mice
sarscov
challeng
find
sarscov
vlp
may
appli
construct
vlp
merscov
compar
inactiv
liveattenu
viru
vaccin
vlp
contain
infecti
materi
make
vlp
technolog
promis
altern
mer
vaccin
develop
howev
immunogen
vlp
rel
lower
inactiv
liveattenu
viru
vaccin
sever
strategi
may
explor
increas
immunogen
vlp
exampl
dendrit
cellstimul
molecul
tolllik
receptor
ligand
flagellin
genet
engin
incorpor
merscov
vlp
increas
immunogen
enhanc
protect
efficaci
heterosubtyp
viru
challeng
subunit
vaccinescompar
type
vaccin
subunit
vaccin
claim
sever
uniqu
advantag
import
characterist
subunit
vaccin
safeti
compon
contain
synthet
peptid
recombin
protein
express
specif
immunogen
fragment
pathogen
without
involv
infecti
virus
addit
type
vaccin
less
like
induc
side
effect
inject
site
consist
product
attain
subunit
vaccin
constant
condit
welldefin
pathogen
fragment
featur
made
subunit
vaccin
attract
vaccin
candid
like
sarscov
protein
protein
merscov
also
consid
import
target
develop
subunit
vaccin
main
antigen
compon
respons
induc
host
immun
respons
sinc
protein
contain
region
receptor
bind
membran
fusion
proteinbas
vaccin
expect
induc
antibodi
block
viru
bind
subsequ
membran
fusion
neutral
viral
infect
howev
protein
sarscov
also
contain
nonneutr
epitop
immmunopredomin
domain
may
induc
harm
immun
respons
therefor
essenti
identifi
exclud
epitop
protein
may
induc
harm
ade
respons
proteinbas
merscov
vaccin
experi
develop
rbdbase
sar
subunit
vaccin
provid
import
guidanc
ration
design
rbd
proteinbas
mer
vaccin
sinc
rbd
sarscov
contain
multipl
neutral
epitop
rbdbase
sar
subunit
vaccin
cover
neutral
epitop
abl
induc
potent
neutral
antibodi
complet
prevent
sarscov
challeng
similarli
shown
rbd
merscov
induc
strong
neutral
antibodi
respons
infect
merscov
merscov
rbd
inde
contain
sever
import
neutral
epitop
accordingli
optim
rbd
develop
optim
rbdbase
mer
subunit
vaccin
contain
multipl
neutral
epitop
would
desir
feasibl
improv
vaccin
efficaci
merscov
sarscov
rbd
consist
core
receptorbind
subdomain
share
high
degre
structur
similar
core
subdomain
receptorbind
subdomain
notabl
diverg
variat
receptorbind
subdomain
region
within
subgroup
coronaviru
across
differ
coronaviru
group
advis
ration
design
mer
subunit
vaccin
use
chimer
protein
contain
sever
neutral
epitop
diverg
subgroup
approach
provid
strateg
platform
ration
design
subunit
vaccin
futur
emerg
cov
focus
chimer
protein
contain
neutral
epitop
multipl
viru
strain
across
differ
subgroup
summar
although
inactiv
liveattenu
viru
viral
vectorbas
vaccin
abl
induc
strong
immun
respons
tendenc
recov
virul
caus
harm
immun
respons
rais
safeti
concern
develop
mer
vaccin
dnabas
vaccin
high
safeti
profil
may
unabl
induc
highli
potent
immun
respons
protect
human
might
caus
toxic
effect
inject
site
repeat
vaccin
comparison
develop
recombin
rbd
proteinbas
mer
subunit
vaccin
remain
high
prioriti
due
varieti
advantag
note
spite
number
merit
proteinbas
subunit
vaccin
might
rel
lower
immunogen
compar
inactiv
liveattenu
vaccin
necessit
continu
improv
immunogen
subunit
vaccin
two
possibl
discuss
potenti
strategi
improv
immunogen
mer
vaccin
candid
formul
subunit
vaccin
suitabl
adjuvantsto
improv
immunogen
mer
candid
vaccin
adjuv
select
formul
basi
mechan
action
normal
vaccin
limit
immunogen
requir
addit
specif
adjuv
stimul
protect
longlast
immun
respons
although
varieti
novel
adjuv
emerg
investig
approv
clinic
use
aluminum
saltbas
adjuv
usual
call
alum
induc
antigenspecif
humor
ctl
respons
henc
potenti
use
merscov
subunit
vaccin
anoth
adjuv
name
glucopyranosyl
lipid
synthet
agonist
also
shown
improv
immunogen
proteinbas
vaccin
candid
adjuv
montanid
approv
human
use
europ
use
make
mer
influenza
subunit
vaccin
demonstr
strong
abil
promot
induct
highli
potent
immun
respons
candid
vaccin
furthermor
combin
two
adjuv
distinct
mechan
action
also
feasibl
improv
efficaci
design
mer
subunit
vaccin
sinc
alum
alon
induc
strong
immun
respons
thu
applic
combin
alum
adjuv
potenti
complementari
effect
hope
improv
efficaci
induc
alumadjuv
subunit
vaccin
exampl
combin
alum
plu
glucopyranosyl
lipid
appli
improv
efficaci
sarscov
rbd
proteinbas
subunit
vaccin
therefor
similar
strategi
util
merscov
subunit
vaccin
improv
immunogen
select
suitabl
administr
routessever
administr
rout
includ
im
intraderm
sc
pathway
use
vaccin
immun
experiment
research
clinic
use
rout
vaccin
administr
directli
influenc
qualiti
quantiti
vaccineinduc
immun
tradit
parenter
administr
rout
im
intraderm
sc
shown
induc
favor
immun
respons
andor
protect
sarscov
merscov
infect
demonstr
imvaccin
rbd
protein
sarscov
elicit
longterm
immun
respons
neutral
activ
protect
immun
mice
sarscov
challeng
addit
potent
neutral
antibodi
protect
sarscov
infect
observ
mice
sc
vaccin
sarscov
rbd
protein
respect
express
mammalian
cell
insect
cell
escherichia
coli
express
system
furthermor
strong
neutral
antibodi
respons
reveal
mice
scvaccin
merscov
rbd
protein
addit
induc
system
immun
stimul
local
immun
mucos
site
becom
import
object
vaccin
although
unfavor
featur
rout
possibl
deliv
antigen
central
nervou
system
well
unsuit
children
younger
year
adult
older
year
especi
chronic
pulmonari
diseas
immunosuppress
advantag
rout
outweigh
disadvantag
report
indic
vaccin
effect
induc
local
system
immun
respons
especi
mucos
iga
mucos
pathogen
crossprotect
vaccin
anim
infect
homolog
heterolog
strain
influenza
viru
well
provid
longterm
protect
sarscov
infect
import
mucos
pathogen
infect
human
via
mucos
pathway
mer
vaccin
deliv
via
mucos
rout
anticip
elicit
effect
mucos
immun
respons
repres
mucos
iga
intranas
immun
subunit
candid
vaccin
contain
recombin
rbd
protein
fuse
fc
human
igg
demonstr
induc
strong
antirbdand
neutral
antibodi
respons
particularli
iga
mucos
immun
respons
infect
merscov
provid
fundament
basi
develop
effect
mer
mucos
vaccin
therefor
select
suitabl
vaccin
rout
combin
antigen
formul
appropri
adjuv
play
import
guidanc
develop
merscov
subunit
vaccin
evalu
efficaci
merscov
infect
establish
effect
anim
model
import
evalu
efficaci
candid
vaccin
merscov
unlik
sarscov
infect
varieti
anim
includ
nonhuman
primat
small
anim
model
ferret
hamster
mice
anim
speci
could
infect
merscov
limit
shown
merscov
unabl
replic
hamster
ferret
mice
significantli
restrict
efficaci
evalu
mer
vaccin
small
anim
model
although
rhesu
macaqu
infect
merscov
infect
anim
show
clinic
sign
diseas
viru
replic
high
cost
nonhuman
primat
model
would
prevent
major
research
use
anim
model
therefor
develop
effect
small
anim
model
merscov
infect
urgent
need
recent
report
mice
transduc
adenovir
vector
express
merscov
receptor
suscept
merscov
infect
infect
mice
develop
pneumonia
clinic
diseas
accompani
histopatholog
chang
nevertheless
better
transgen
mous
model
gene
encod
human
integr
genom
develop
sever
laboratori
base
previou
experi
develop
sarscov
vaccin
current
advanc
potenti
strategi
develop
merscov
vaccin
discuss
review
apart
inactiv
liveattenu
viru
vaccin
dnaand
vlpbase
vaccin
particularli
subunit
vaccin
contain
rbd
merscov
protein
critic
import
addit
suitabl
adjuv
formul
appropri
administr
rout
may
need
consid
enhanc
immunogen
vaccin
candid
furthermor
develop
effect
anim
model
merscov
infect
import
evalu
efficaci
merscov
candid
vaccin
taken
togeth
strategi
discuss
import
implic
develop
effect
mer
vaccin
futur
merscov
newli
emerg
coronaviru
rais
worldwid
concern
base
abil
caus
increas
number
human
infect
limit
humantohuman
transmiss
make
particularli
import
explor
effici
safe
measur
control
diseas
among
vaccin
consid
one
effect
strategi
prevent
viru
infect
differ
structur
protein
e
n
protein
merscov
play
key
role
viru
infect
via
bind
viral
receptor
follow
subsequ
viru
cell
membran
fusion
via
identifi
cellular
receptor
merscov
subsequ
viral
rbd
map
crystal
structur
analysi
residu
subunit
protein
truncat
rbd
contain
residu
induc
highest
neutral
antibodi
respons
viru
infect
vaccin
anim
thu
demonstr
import
develop
srbdbase
vaccin
merscov
compar
vaccin
type
subunit
vaccin
possess
higher
safeti
profil
potenti
elicit
stronger
immun
respons
includ
neutral
antibodi
suitabl
choic
adjuv
formul
immun
rout
increas
efficaci
subunit
vaccin
highlight
need
develop
merscov
subunit
vaccin
base
rbd
viral
protein
next
year
develop
effect
safe
subunit
vaccin
mer
expect
particular
develop
subunit
vaccin
base
rbd
merscov
protein
greatest
potenti
contain
multipl
neutral
epitop
capabl
induc
highli
potent
immun
respons
particularli
neutral
activ
merscov
infect
establish
effect
small
anim
model
mer
infect
allow
econom
practic
detect
protect
efficaci
design
vaccin
challeng
singl
multipl
merscov
strain
potenti
occur
human
applic
similar
vaccin
develop
strategi
cov
might
caus
human
diseas
futur
also
anticip
first
identifi
human
june
middl
east
respiratori
syndrom
mer
newli
emerg
infecti
diseas
caus
novel
coronaviru
merscoronaviru
merscov
current
caus
increas
human
infect
high
mortal
belong
lineag
c
phylogenet
relat
merscov
first
known
lineag
c
associ
human
infect
human
dipeptidyl
peptidas
identifi
receptor
merscov
receptorbind
domain
rbd
merscov
map
crystal
structur
residu
cover
respect
truncat
rbd
fragment
contain
acid
residu
merscov
protein
induc
strong
rbdspecif
antibodi
block
merscov
rbd
bind
viral
receptor
dipeptidyl
peptidas
effect
neutral
merscov
infect
provid
promis
develop
mer
candid
vaccin
merscov
protein
rbdbase
subunit
vaccin
contain
multipl
neutral
epitop
possess
high
efficaci
induc
strong
neutral
antibodi
respons
protect
immun
merscov
infect
repres
direct
futur
design
effect
mer
vaccin
subunit
vaccin
formul
suitabl
adjuv
administ
appropri
rout
high
potenti
enhanc
immunogen
mer
candid
vaccin
